Last reviewed · How we verify
Dapagliflozin+ACEI treatment
Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to reduce blood glucose, while an ACE inhibitor blocks angiotensin-converting enzyme to lower blood pressure and reduce proteinuria.
Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to reduce blood glucose, while an ACE inhibitor blocks angiotensin-converting enzyme to lower blood pressure and reduce proteinuria. Used for Type 2 diabetes mellitus with hypertension or chronic kidney disease.
At a glance
| Generic name | Dapagliflozin+ACEI treatment |
|---|---|
| Also known as | Treatment group |
| Sponsor | Children's Hospital of Fudan University |
| Drug class | SGLT2 inhibitor + ACE inhibitor combination |
| Target | SGLT2 and ACE |
| Modality | Small molecule |
| Therapeutic area | Diabetes, Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Dapagliflozin is an SGLT2 inhibitor that promotes urinary glucose excretion independent of insulin, thereby lowering blood glucose levels. The ACE inhibitor component blocks the renin-angiotensin-aldosterone system, reducing blood pressure and providing renal protection. This combination targets both glycemic control and cardiovascular/renal outcomes in diabetes management.
Approved indications
- Type 2 diabetes mellitus with hypertension or chronic kidney disease
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Hypotension
- Cough (ACE inhibitor-related)
- Hyperkalemia
Key clinical trials
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (NA)
- Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs (NA)
- FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan (PHASE3)
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
- DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction (PHASE3)
- An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
- Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy? (PHASE4)
- STunning in Acute Myocardial Infarction - BAS (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |